Trial Profile

The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary)
Indications Coronary artery disease; Myocardial infarction; Stroke
Focus Adverse reactions
Acronyms METCHNIKOFF

Most Recent Events

06 Mar 2023 Results assessing the effects of Evolocumab on plasma lipids and circulating immune cell transcriptional responses to Toll-like receptor (TLR) activation, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
11 Jul 2022 Status changed from recruiting to completed.
25 Aug 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com